Literature DB >> 10997521

Idiopathic hyperostosis of the calvaria in five young bullmastiffs.

K F Pastor1, J P Boulay, S H Schelling, J L Carpenter.   

Abstract

A new calvarial hyperostotic syndrome (CHS) in young bullmastiffs is described. Calvarial hyperostotic syndrome clinically resembles canine craniomandibular osteopathy (CMO) and human infantile cortical hyperostosis (ICH), but it is unique in that there is progressive and often asymmetric skull bone involvement, and the population affected appears to be only young, male bullmastiff dogs. Characteristic radiographic findings consist of cortical thickening of the calvaria with irregular, bony proliferation over the frontal, temporal, and occipital bones. Histopathological examination shows that the trabeculae of the calvarial diploë are thickened and contiguous with a sunburst-like pattern of subperiosteal trabeculae composed of woven and lamellar bone tissue, accompanied by loose fibrovascular tissue and a variable inflammatory response comprised predominantly of neutrophils. In 80% of the cases presented, the lesion was self-limiting. The etiology remains unknown; however, traumatic, neoplastic, and degenerative conditions do not appear to be primary factors in the etiopathogenesis of the syndrome. It may be that this syndrome has a familial component, similar to that described for CMO and ICH.

Entities:  

Mesh:

Year:  2000        PMID: 10997521     DOI: 10.5326/15473317-36-5-439

Source DB:  PubMed          Journal:  J Am Anim Hosp Assoc        ISSN: 0587-2871            Impact factor:   1.023


  2 in total

1.  Craniomandibular osteopathy in a bullmastiff.

Authors:  Stacey L Huchkowsky
Journal:  Can Vet J       Date:  2002-11       Impact factor: 1.008

2.  Whole Genome Sequencing Indicates Heterogeneity of Hyperostotic Disorders in Dogs.

Authors:  Anna Letko; Fabienne Leuthard; Vidhya Jagannathan; Daniele Corlazzoli; Kaspar Matiasek; Daniela Schweizer; Marjo K Hytönen; Hannes Lohi; Tosso Leeb; Cord Drögemüller
Journal:  Genes (Basel)       Date:  2020-02-04       Impact factor: 4.096

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.